Last reviewed · How we verify
Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer (TICTOC)
The study's purpose is to understand the effects of a new treatment (suba-itraconazole and tamoxifen) in epithelial ovarian cancer. Who is it for? Patients may be eligible to join this study with ovarian cancer resistant to platinum-based chemotherapy agents Study Details: Participants will receive different doses of tamoxifen and suba-itraconazole to determine the optimal combination dose. Participants will be seen by the investigators once a week for the first 3 weeks and then once every 4 weeks. Participant will be reviewed by a clinician and undergo regular blood tests, cardiac monitoring and imaging assessments.
Details
| Lead sponsor | Anthony Joshua, FRACP |
|---|---|
| Phase | PHASE1 |
| Status | ACTIVE_NOT_RECRUITING |
| Enrolment | 44 |
| Start date | Sun Sep 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Jan 01 2027 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Ovarian Cancer
Interventions
- SUBA-itraconazole
- Tamoxifen
Countries
Australia